tetano
Editor, Senior Moderator
ASAIO J
. 2024 Jan 19.
doi: 10.1097/MAT.0000000000002132. Online ahead of print. Noninvasive Ventilation Before Intubation and Mortality in Patients Receiving Extracorporeal Membrane Oxygenation for COVID-19: An Analysis of the Extracorporeal Life Support Organization Registry
Marco Giani[SUP] 1 [/SUP], Emanuele Rezoagli[SUP] 1 [/SUP], Ryan P Barbaro[SUP] 2 [/SUP], Jordi Riera[SUP] 3 [/SUP], Giacomo Bellani[SUP] 4 [/SUP], Laurent Brochard[SUP] 5 6 [/SUP], Alain Combes[SUP] 7 [/SUP], Giuseppe Foti[SUP] 1 [/SUP], Daniel Brodie[SUP] 8 [/SUP]
Affiliations
Bilevel-positive airway pressure (BiPAP) is a noninvasive respiratory support modality which reduces effort in patients with respiratory failure. However, it may increase tidal ventilation and transpulmonary pressure, potentially aggravating lung injury. We aimed to assess if the use of BiPAP before intubation was associated with increased mortality in adult patients with coronavirus disease 2019 (COVID-19) who received venovenous extracorporeal membrane oxygenation (ECMO). We used the Extracorporeal Life Support Organization Registry to analyze adult patients with COVID-19 supported with venovenous ECMO from January 1, 2020, to December 31, 2021. Patients treated with BiPAP were compared with patients who received other modalities of respiratory support or no respiratory support. A total of 9,819 patients from 421 centers were included. A total of 3,882 of them (39.5%) were treated with BiPAP before endotracheal intubation. Patients supported with BiPAP were intubated later (4.3 vs. 3.3 days, p < 0.001) and showed higher unadjusted hospital mortality (51.7% vs. 44.9%, p < 0.001). The use of BiPAP before intubation and time from hospital admission to intubation resulted as independently associated with increased hospital mortality (odds ratio [OR], 1.32 [95% confidence interval {CI}, 1.08-1.61] and 1.03 [1-1.06] per day increase). In ECMO patients with severe acute respiratory failure due to COVID-19, the extended use of BiPAP before intubation should be regarded as a risk factor for mortality.
. 2024 Jan 19.
doi: 10.1097/MAT.0000000000002132. Online ahead of print. Noninvasive Ventilation Before Intubation and Mortality in Patients Receiving Extracorporeal Membrane Oxygenation for COVID-19: An Analysis of the Extracorporeal Life Support Organization Registry
Marco Giani[SUP] 1 [/SUP], Emanuele Rezoagli[SUP] 1 [/SUP], Ryan P Barbaro[SUP] 2 [/SUP], Jordi Riera[SUP] 3 [/SUP], Giacomo Bellani[SUP] 4 [/SUP], Laurent Brochard[SUP] 5 6 [/SUP], Alain Combes[SUP] 7 [/SUP], Giuseppe Foti[SUP] 1 [/SUP], Daniel Brodie[SUP] 8 [/SUP]
Affiliations
- PMID: 38237635
- DOI: 10.1097/MAT.0000000000002132
Bilevel-positive airway pressure (BiPAP) is a noninvasive respiratory support modality which reduces effort in patients with respiratory failure. However, it may increase tidal ventilation and transpulmonary pressure, potentially aggravating lung injury. We aimed to assess if the use of BiPAP before intubation was associated with increased mortality in adult patients with coronavirus disease 2019 (COVID-19) who received venovenous extracorporeal membrane oxygenation (ECMO). We used the Extracorporeal Life Support Organization Registry to analyze adult patients with COVID-19 supported with venovenous ECMO from January 1, 2020, to December 31, 2021. Patients treated with BiPAP were compared with patients who received other modalities of respiratory support or no respiratory support. A total of 9,819 patients from 421 centers were included. A total of 3,882 of them (39.5%) were treated with BiPAP before endotracheal intubation. Patients supported with BiPAP were intubated later (4.3 vs. 3.3 days, p < 0.001) and showed higher unadjusted hospital mortality (51.7% vs. 44.9%, p < 0.001). The use of BiPAP before intubation and time from hospital admission to intubation resulted as independently associated with increased hospital mortality (odds ratio [OR], 1.32 [95% confidence interval {CI}, 1.08-1.61] and 1.03 [1-1.06] per day increase). In ECMO patients with severe acute respiratory failure due to COVID-19, the extended use of BiPAP before intubation should be regarded as a risk factor for mortality.